Skip to main content
Figure 2 | Retrovirology

Figure 2

From: A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants

Figure 2

Chemical structures of rilpivirine analogues. Analogues differed from rilpivirine (1, boxed) by the addition of an exocyclic moiety to the pyrimidine ring in either of its ‘flipped’ conformations (69), the replacement of the pyrimidine ring with a 2,6-purine ring system in ‘flipped’ conformations with or without a protecting group (1013), replacing the 4-benzonitrile moiety in addition to replacing the pyrimidine ring with a 2,6-purine (1425), or replacing the pyrimidine ring with a 2,9-purine ring system (26, 27). Differences between each analogue and rilpivirine are indicated in red.

Back to article page